• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Orion

70.50 EUR

-2.08 %

14,429 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-2.08 %
+0.93 %
-1.67 %
+11.37 %
+10.76 %
+11.73 %
+86.95 %
+91.47 %
+527.78 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
9.95B EUR
Turnover
10.65M EUR
P/E (adj.) (26e)
17.98
EV/EBIT (adj.) (26e)
14.01
P/B (26e)
6.24
EV/S (26e)
4.76
Dividend yield-% (26e)
2.53 %
Coverage
Recommendation
Buy
Target price
80.00 EUR
Updated
23.04.2026
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 24.04.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
This was an unfamiliar concept to me, so here is a summary in case it is unfamiliar to anyone else: Drugs that have been granted orphan drug status are offered scientific and administrative advice, as well as reductions in marketing authorization and other regulatory fees. After ...
6/23/2026, 6:41 AM
by Paapaa
14
Orion Oyj (Orion Pharma) has been granted Orphan Drug Designation (Orphan Designation) by the European Commission, following a recommendation from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP), for its investigational drug ODM-212 for the treatment...
6/23/2026, 6:35 AM
by Ilkka
13
Well, why not! It took the competing TEAD inhibitor VT3989 ~5 years to get from the start of the clinical program to the beginning of Phase 3. On this timeline, Orion’s Phase 3 could be completed by ~2034 and launch, for example, in 2035. In theory, of course, an accelerated marketing...
6/2/2026, 8:15 PM
by Antti Siltanen
13
Insights from the ASCO 2026 mega-cancer conference: a randomized “androgen inhibitor” comparison in prostate cancer, 111 patients, open-label phase 2. ascopost.com Alicia K. Morgans, MD, FASCO, on Cognitive Effects of Darolutamide vs... https://www.asco.org/abstracts-presentations...
6/3/2026, 8:08 AM
by Vino Pino
11
Here are Antti’s comments on the first results of Orion’s ODM-212 candidate Orion announced over the weekend preliminary results from the Phase I/II clinical trial of the cancer drug candidate ODM-212. Based on the results presented at the ASCO congress, the drug candidate has been...
6/1/2026, 5:51 AM
by Sijoittaja-alokas
11
The ASCO abstract for the First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES) has been published: First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES). - ASCO As with other similar early-...
5/22/2026, 7:55 AM
by Vino Pino
10
Inderes Orion Pharma julkisti ensimmäiset tulokset Faasi 1/2 TEADES-tutkimuksesta... ORION OYJ LEHDISTÖTIEDOTE 30.5.2026 KLO 21.30 Orion Pharma julkisti ensimmäiset tulokset Faasi 1/2 TEADES-tutkimuksesta ODM-212-molekyylillä (TEAD-estäjä) potilailla, joilla on kiinteitä kasvaimia...
5/30/2026, 6:51 PM
by Dissidentti
9
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.7
2026

Interim report Q2'26

19.10
2026

Half year dividend

28.10
2026

Interim report Q3'26

Press release03.07.2026, 08.00

Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026

Orion
Orion indgår aftale om rettigheder til vigtigt biosimilært lægemiddel i Europa
Analyst Comment30.06.2026, 07.55 by
Antti Siltanen

Orion indgår aftale om rettigheder til vigtigt biosimilært lægemiddel i Europa

Rettighederne til en biosimilær version af et kræftlægemiddel til 10 mia. EUR giver vækstpotentiale, men løfter endnu ikke estimaterne.

Orion
Press release30.06.2026, 07.00

Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market

Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Orions ODM-212 fik også særstatus som lægemiddel i EU
Analyst Comment24.06.2026, 06.00 by
Antti Siltanen

Orions ODM-212 fik også særstatus som lægemiddel i EU

Særstatus som lægemiddel til sjældne sygdomme giver ODM-212-kandidaten eksklusivitet på markedet i op til 10 år.

Orion
Press release23.06.2026, 08.30

Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission

Orion
Regulatory press release18.06.2026, 13.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release17.06.2026, 15.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release16.06.2026, 15.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release15.06.2026, 15.15

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release11.06.2026, 16.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release10.06.2026, 17.10

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release05.06.2026, 16.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release01.06.2026, 13.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Orion: Første resultater fra lægemiddelkandidat ODM-212
Analyst Comment01.06.2026, 07.34 by
Antti Siltanen

Orion: Første resultater fra lægemiddelkandidat ODM-212

Fase I/II-studiet er allerede fortsat til næste del.

Orion
Press release30.05.2026, 20.30

Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

Orion
Press release21.05.2026, 09.30

Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting

Orion
Regulatory press release15.05.2026, 08.00

105,950 Orion Corporation A shares converted into B shares

Orion
Press release12.05.2026, 09.30

Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs

Orion
Regulatory press release04.05.2026, 15.00

Orion Corporation: Managers’ transactions – Ari Lehtoranta

Orion
Regulatory press release04.05.2026, 15.00

Orion Corporation: Managers’ transactions – Sophie Papa

Orion